Literature DB >> 7781274

Contemporary laboratory monitoring of low molecular weight heparins.

M M Samama1, L Poller.   

Abstract

Low molecular weight heparins are widely used in the prophylaxis and treatment of thromboembolic accidents. Laboratory monitoring seems restricted to the treatment of established thrombosis. Repeated controls of platelet count are mandatory.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7781274

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  14 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.

Authors:  Jonathan P Singer; Meng-Yu Huang; Christine Hui; Paul D Blanc; Rebecca F Boettger; Jeffery Golden; Katherine Watkins; Charles Hoopes; Lorriana E Leard
Journal:  J Heart Lung Transplant       Date:  2010-06-08       Impact factor: 10.247

Review 3.  Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

Authors:  B S Smith; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

4.  Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.

Authors:  Todd W Costantini; Emily Min; Kevin Box; Vy Tran; Robert D Winfield; Dale Fortlage; Jay Doucet; Vishal Bansal; Raul Coimbra
Journal:  J Trauma Acute Care Surg       Date:  2013-01       Impact factor: 3.313

Review 5.  Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

Authors:  Jeremy W Vandiver; Leticia I Ritz; Jeffrey T Lalama
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

6.  Haemorrhagic complications in patients with renal insufficiency during treatment or prophylaxis with dalteparin.

Authors:  Estrella Díaz Gómez; David Suárez Del Olmo; Laura Corregidor Luna; Irene Iglesias-Peinado; Benito García Díaz
Journal:  Eur J Hosp Pharm       Date:  2020-09-12

7.  Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial.

Authors:  Jie-Qiong Song; Li-Zhen Xuan; Wei Wu; Jun-Feng Huang; Ming Zhong
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

8.  Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.

Authors:  Charles A Karcutskie; Arjuna Dharmaraja; Jaimin Patel; Sarah A Eidelson; Anish B Padiadpu; Arch G Martin; Gabriel Lama; Edward B Lineen; Nicholas Namias; Carl I Schulman; Kenneth G Proctor
Journal:  JAMA Surg       Date:  2018-02-01       Impact factor: 14.766

Review 9.  Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).

Authors:  Claire Dunois
Journal:  Biomedicines       Date:  2021-04-21

10.  Fondaparınux versus nadroparın for preventıon of venous thromboembolısm after electıve hıp and knee arthroplasty.

Authors:  Mahmut Argun; Mithat Oner; Mehmet Saglamoglu; Ibrahim Karaman; Ahmet Guney; Mehmet Halici; Ibrahim Halil Kafadar
Journal:  Curr Ther Res Clin Exp       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.